June 14, 2013

What It Means for $MRK to be a Dark Horse for $PVCT

Dr. Perlmutter was responsible for Amgen's acquisition of BioVex and its principal drug compound OncoVEX, now T-Vec (talimogene laherparepvec). T-Vec is a competitor of PV-10.

Perlmutter now runs Merck's R&D organization. Merck's licensing group/function now reports to him, and Dr. Perlmutter is keenly interested in business development and licensing.

Thank you to the blog reader who indicated the prior $MRK posts were hazy in their implication.

Implication: Merck may well be a serious contender [to Pfizer] to license PV-10.

No comments:

Post a Comment